CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
Increased Risk in Patients With High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary Intervention
Is the Current Antiplatelet Therapy Adequate?
Kevin P. Bliden, BS,
Joseph DiChiara, BS,
Udaya S. Tantry, PhD,
Ashwani K. Bassi, MD,
Srivasavi K. Chaganti, MD and
Paul A. Gurbel, MD*
Sinai Center for Thrombosis Research, Baltimore, Maryland
Manuscript received July 28, 2006;
accepted October 1, 2006.
* Reprint requests and correspondence: Dr. Paul A. Gurbel, Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 West Belvedere Avenue, Baltimore, Maryland 21215. (Email: pgurbel{at}lifebridgehealth.org).
 |
Abstract
|
|---|
OBJECTIVES: We sought to determine whether patients receiving chronic clopidogrel therapy undergoing nonemergent stenting who display high on-treatment preprocedural platelet aggregation measured by standard light transmittance aggregometry and thrombelastography (TEG) will be at increased risk for poststenting ischemic events.
BACKGROUND: Patients exhibiting heightened platelet reactivity to adenosine diphosphate (ADP) might be at increased risk for recurrent ischemic events after coronary stenting.
METHODS: A total of 100 consecutive patients receiving chronic antiplatelet therapy consisting of aspirin (325 mg qd) and clopidogrel (75 mg qd) were studied before undergoing nonemergent stenting. Patients were followed for 1 year after coronary stenting for the occurrence of death, myocardial infarction, stent thrombosis, stroke, or ischemia requiring a hospital stay.
RESULTS: All patients were aspirin responsive. Patients with ischemic events (23 of 100, 23%) within 1 year had greater on-treatment prestent ADP-induced platelet aggregation than patients without ischemic events by aggregometry and TEG (p < 0.001 for both measurements). Of patients with an ischemic event, 70% and 87% displayed high on-treatment platelet reactivity at baseline by aggregometry and TEG, respectively. High on-treatment platelet reactivity as measured by aggregometry and TEG were the only variables significantly related to ischemic events (p < 0.001 for both assays). The administration of eptifibatide reduced periprocedural elevation in platelet reactivity, with no significant differences in bleeding events.
CONCLUSIONS: Patients receiving chronic clopidogrel therapy undergoing nonemergent percutaneous coronary intervention who exhibit high on-treatment ADP-induced platelet aggregation are at increased risk for postprocedural ischemic events. These findings might have implications for the alteration in clopidogrel maintenance dose and use of glycoprotein IIb/IIIa inhibitors in selected patients.
|
Abbreviations and Acronyms
| | AA = arachidonic acid | | ADP = adenosine diphosphate | | GP = glycoprotein | | HPR = high on-treatment platelet reactivity | | LTA = light transmittance aggregometry | | NPR = normal on-treatment platelet reactivity | | PCI = percutaneous coronary intervention | | TEG = thrombelastograph(y) |
|
Platelet aggregation is a central process in the development of ischemic complications after percutaneous coronary intervention (PCI) (1–4). Dual antiplatelet therapy with aspirin and clopidogrel are the gold standard to attenuate platelet function during PCI. However, despite the superior protection documented in clinical trials with dual antiplatelet therapy, it has been demonstrated that nearly 20% of patients undergoing PCI will experience recurrent ischemic or thrombotic events (5). It has been repeatedly shown that a significant percentage of patients display no demonstrable antiplatelet effect by ex vivo measurements after a 300-mg clopidogrel loading dose (6,7). It has been hypothesized that patients exhibiting clopidogrel nonresponsiveness and heightened platelet reactivity to adenosine diphosphate (ADP) are inadequately protected and might be at increased risk for recurrent events (6,8).
A relationship between clopidogrel nonresponsiveness and post-PCI ischemic events in clopidogrel-naïve patients has been recently suggested (5,9–11). Clinical studies indicated that postprocedural heightened platelet reactivity is associated with increased myocardial necrosis and inflammation marker release (3,12). Furthermore, increased post-treatment platelet reactivity has been associated with recurrent ischemic events and stent thrombosis (4,5,11). These studies emphasize the potentially sizeable risks associated with inadequate platelet inhibition from current antiplatelet therapy.
Among patients receiving maintenance dose clopidogrel therapy, a certain percentage display heightened platelet reactivity to ADP (4,6,13). Despite this evidence, there is no established recommendation for clopidogrel loading in patients receiving chronic clopidogrel therapy undergoing PCI. Furthermore, there are no sufficient data correlating heightened platelet reactivity with adverse cardiovascular events in these patients. The goal of the present study was to quantify this relationship. We hypothesized that patients receiving chronic clopidogrel therapy undergoing non-emergent PCI who display high preprocedural platelet reactivity, as measured by standard light transmittance aggregometry (LTA) and thrombelastography (TEG), are at increased risk for post-PCI ischemic events.
|
Methods
|
|---|
This study was approved by the investigational review board. One hundred consecutive patients receiving clopidogrel therapy (75 mg qd) for  1 month before undergoing non-emergent coronary stenting were enrolled after giving informed consent. A clopidogrel loading dose was not administered. All patients had received at least 81 mg aspirin for 7 days before the procedure. Patients were >18 years old. The exclusion criteria were: a history of bleeding diathesis, acute myocardial infarction within 48 h, elevated cardiac markers (above upper limits normal for the respective assay), cerebrovascular event within 3 months, illicit drug or alcohol abuse, prothrombin time >1.5 times control, platelet count <100,000/mm3, hematocrit <30%, creatinine >4.0 mg/dl, and glycoprotein (GP) IIb/IIIa use before the procedure.
On the day of the procedure and daily thereafter, 325 mg aspirin was administered. Eptifibatide was administered at the discretion of the treating physician with the ESPRIT (Evaluation of Subcutaneous Proleukin in a Randomized International Trial) study protocol as a double bolus (180 µg/kg) followed by an infusion (2 µg/kg/min) for 18 to 24 h after procedure. Unfractionated heparin was administered according to the ESPRIT dosing regimen (60 U/kg) as a bolus to all patients in the catheterization laboratory immediately before stenting (14). Clopidogrel was prescribed in all patients for at least 6 months after procedure.
Blood sampling.
Baseline blood samples were obtained from patients in a fasting state in the catheterization laboratory through the indwelling femoral vessel sheath. Samples were transferred to separate vacutainer blood collecting tubes (Becton-Dickinson, Franklin Lakes, New Jersey) containing 3.8% trisodium citrate or lithium heparin. After discarding the first 2 to 3 ml of free flowing blood, the vacutainer tubes were filled to capacity and gently inverted 3 to 5 times to ensure complete mixing of the anticoagulant. Baseline samples were obtained before coronary intervention and at 3 h and 18 to 24 h after stenting. In patients treated with eptifibatide, the 18 to 24 h blood draw was performed within 1 h after completion of the eptifibatide infusion.
Platelet aggregation.
The blood-citrate tubes were centrifuged at 120 g for 5 min to recover platelet rich plasma (PRP) and further centrifuged at 850 g for 10 min to recover platelet poor plasma (PPP). The PRP and PPP were stored at room temperature to be used within 2 h. Platelet aggregation was assessed as described previously (3). Briefly, platelets were stimulated with 5 µmol/l ADP and 1 mmol/l arachidonic acid (AA). Aggregation was assessed with a Chronolog Lumi-Aggregometer (Model 490-4D) with the Aggrolink software package (Chronolog, Havertown, Pennsylvania). Aggregation was expressed as the maximum percent change in light transmittance from baseline, with PPP as a reference.
Thrombelastograph Hemostasis Analyzer With PlateletMapping.
The Food and Drug Administration-approved Thrombelastograph Hemostasis Analyzer With PlateletMapping assay (Haemoscope Corp., Niles, Illinois) relies on the measurement of thrombin-induced clot strength to enable a quantitative analysis of platelet function (15,16). The assay uses heparin as an anticoagulant to eliminate thrombin activity in the sample. Reptilase and factor XIIIa (activator F) are used to generate a cross-linked fibrin clot to isolate the fibrin contribution to clot strength (17). The contribution of P2Y12 receptor or cyclooxygenase pathways to the clot formation can be measured by the addition of the appropriate agonist, ADP or AA.
Blood was analyzed according to the manufacturer's instructions. One milliliter heparinized blood was transferred to a vial containing kaolin and mixed by inversion. Five hundred microliters of the activated blood were then transferred to a vial containing heparinase and mixed to neutralize heparin. The neutralized blood (360 µl) was immediately added to a heparinase-coated cup and assayed in the TEG analyzer to measure the thrombin-induced clot strength (MAthrombin). Heparinized blood (340 µl) was added to a noncoated cup containing reptilase and activator F to generate a whole blood crosslinked clot in the absence of thrombin generation or platelet stimulation (MAfibrin). A third sample (340 µl) of heparinized blood was added to a nonheparinase-coated cup in the presence of the activator F and ADP (2 µmol) or AA (1 mmol/l) to generate a whole blood-crosslinked clot with platelet activation (MAADP or MAAA). Platelet aggregation in response to ADP or AA is calculated with computerized software on the basis of the formula: %Aggregation = [(MAADP or AA– MAfibrin)/(MAthrombin – MAfibrin)] x 100 (Fig. 1).
View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Thrombelastograph PlateletMapping Analysis Parameters
MAThrombin = measure of maximum thrombin-induced platelet-fibrin clot strength; MAFibrin = contribution of fibrin to clot strength; MAADP or AA = represents clot strength after adenosine diphosphate (ADP) or arachidonic acid (AA) stimulation.
|
|
Definitions and clinical outcomes.
High on-treatment platelet reactivity
The cut points for high on-treatment platelet reactivity (HPR) were defined as 50% ADP-induced platelet aggregation after stimulation with 5-µmol ADP at baseline as measured by LTA or 70% ADP-induced aggregation with 2-µmol ADP at baseline as measured by TEG (17). All patients below these cut points were defined as exhibiting normal on-treatment platelet reactivity (NPR). All tables are representative of 5 µmol/l ADP-induced LTA aggregation values.
Aspirin resistance
Aspirin resistance was defined as >20% platelet aggregation after stimulation by 1-mmol/l AA as measured by LTA or more than 50% platelet aggregation after stimulation by 1-mmol/l AA as measured by TEG (18).
Clinical outcomes
Patients were contacted by telephone at 1, 6, and 12 months to identify the occurrence of adverse events. Patient records including electronic source documents were obtained and reviewed by 2 physicians blinded to the study who adjudicated events. Ischemic events were defined as: death secondary to any cardiovascular cause, stroke, myocardial infarction (in-hospital and after discharge), ischemia requiring a hospital stay, and target vessel revascularization (TVR), nontarget vessel revascularization (NTVR), or medical management. Myocardial infarction was defined as the occurrence of ischemic symptoms and a troponin-I value > upper limits of normal (>1.5 ng/ml). Unstable angina was defined as the occurrence of ischemic symptoms requiring a hospital stay. Bleeding was quantified according to the Thrombolysis In Myocardial Infarction (TIMI) criteria (19). In brief, minor bleeding was defined as clinically overt bleeding accompanied by a fall in hemoglobin of 3.0 to 5.0 g/dl or a fall in hematocrit of 9% to <15%. Major bleeding occurred when the hemoglobin decreased >5 g/dl or the hematocrit decreased 15%.
Statistical analysis.
Categorical variables are expressed as n (%), and continuous variables are expressed as mean ± SD with p < 0.05 considered statistically significant. The Fischer Exact test and Mann-Whitney Rank Sum test were used for comparison of categorical and continuous variables between platelet reactivity groups. Multivariate Cox regression analysis was used to evaluate the significance of the following variables concerning ischemic events within 1 year of follow-up: HPR (measured by TEG and LTA), age, history of diabetes, history of hypertension, smoking (current), bare-metal stent (BMS) versus drug-eluting stent (DES), and patients presenting post-acute coronary syndrome. Pearson product moment correlation was used to measure the correlation between LTA and TEG assays. All statistical calculations for the aforementioned analyses were performed with SigmaStat software (Point Richmond, California). A receiver operator curve (ROC) analysis was used to determine the ability of LTA and TEG to predict ischemic events. This analysis was performed with MedCalc software (Mariakerke, Belgium).
Determination of sample size.
It has been demonstrated that approximately 20% of patients with a history of prior coronary revascularization undergoing repeat PCI will experience a recurrent ischemic event within 1 year of repeat coronary intervention (20). We have previously demonstrated that patients in the upper quartile of platelet reactivity are at approximately 3 times greater risk for repeat ischemic events (17). Therefore, we hypothesized that 30% and 10% of patients with HPR and NPR in the current study will experience a recurrent ischemic event, respectively. With the sample size calculation from SigmaStat software, it is estimated that the sample size required for 95% power with the alpha of 0.05 is approximately 100 patients.
|
Results
|
|---|
Patients.
One hundred patients receiving chronic clopidogrel (1 month) and aspirin therapy were enrolled. Among these patients, 12 were admitted with myocardial infarction (enrolled 48 h after infarction) and 13 had unstable angina. The remainder of the patients had stable angina, and the procedures were nonemergent. A total of 30 patients received treatment with GP IIb/IIIa inhibitors at the discretion of the physician. Serial platelet assays were completed for all subjects.
Demographics.
Patient demographics and procedural characteristics are shown in Tables 1 and 2, respectively. Briefly, cardiovascular risk factors and multivessel interventions using drug-eluting stents were common. No significant differences in age, gender, ethnicity, body mass index, baseline medications or hematological data existed between reactivity groups. Patients with HPR exhibited a higher prevalence of hypertension, diabetes, and use of calcium-channel blockers.
Platelet aggregation.
All patients were aspirin responsive. Mean preprocedural ADP-induced platelet aggregation was 38 ± 16% as measured by LTA and 55 ± 21% as measured by TEG (Table 3). Baseline on-treatment aggregation was significantly higher in patients with ischemic events than in patients without events as measured by LTA (50 ± 13% vs. 31 ± 13% respectively, p < 0.0001) (Fig. 2A) and TEG (76 ± 13% vs. 49 ± 13% respectively, p < 0.0001) (Fig. 2B). A strong correlation was shown between these assays (p < 0.0001, r = 0.82) (Fig. 3).
View larger version (23K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Relation of HPR to Ischemic Events
(A) Graph demonstrating percentage of patients with and without ischemic events displaying high on-treatment platelet reactivity (HPR) as measured by 5 µmol/l adenosine diphosphate (ADP)-induced light transmittance aggregometry. Dashed line indicates cut point for HPR. (B) Graph demonstrating percentage of patients with and without ischemic events displaying HPR as measured by 2-µmol/l ADP-induced thrombelastography. Dashed line indicates cut point for HPR.
|
|
Ischemic events.
One-year follow-up data were completed for all patients. A total of 26 ischemic events occurred in 23 patients (23%) within 1 year of discharge (Table 4). There were no strokes or in-hospital deaths. One patient in the NPR group (presenting with unstable angina) and 2 patients in the HPR group (1 presenting with unstable angina and 1 undergoing non-emergent PCI) suffered periprocedural myocardial infarctions, and 2 patients in the HPR group developed subacute stent thrombosis within 1 week of revascularization. Of the 23 patients (30%), 7 suffered ischemic events after completion of their prescribed clopidogrel treatment. The mean time from discharge to initial event occurrence was 147 ± 106 days (Fig. 4).
Relation of HPR to events.
Of patients with an ischemic event, 70% displayed HPR at baseline, whereas only 8% of patients without an ischemic event displayed HPR at baseline as measured by LTA (Fig. 2A). Similarly, the TEG assay demonstrated that 87% of patients with an ischemic event displayed baseline HPR, whereas only 17% of patients without an ischemic event displayed baseline HPR (Fig. 2B). This resulted in positive predictive values of 73% and 67% and negative predictive values of 91% and 94% for the LTA and TEG, respectively, demonstrating 87% test efficiency with the LTA and 85% test efficiency with the TEG. By analyzing the area under a combined receiver-operating characteristic (ROC) curve, LTA and TEG demonstrated the ability to distinguish between ischemic and nonischemic groups (area = 0.862, p = 0.0001 for LTA; area = 0.881, p = 0.0001 for TEG) (Fig. 5). Within the total group, 16 patients exhibited concordant HPR as measured by both LTA and TEG, 21 patients demonstrated discordant HPR by either LTA or TEG, and the remaining 63 patients displayed NPR as measured by both assays. Eighty-eight percent of patients with concordant HPR, 29% of patients with discordant HPR, and 5% of patients with NPR suffered ischemic events. Despite the higher prevalence of hypertension, diabetes, and use of calcium channel blockers in patients with HPR, analysis with multivariate Cox regression demonstrated no prognostic significance between these risk factors and ischemic events. High on-treatment platelet reactivity as measured by LTA and TEG were the only variables significantly related to ischemic events (p < 0.001) (Table 5).
View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 5 Combined Receiver-Operator Curve for LTA and TEG
Combined receiver-operating characteristic curve for 5-µmol/l ADP-induced LTA and 2-µmol/l ADP-induced TEG at baseline. An area of 0.862 and an area of 0.881 were observed below the curves of LTA and TEG, respectively, with p = 0.0001 for both areas. AUC = area under the curve; other abbreviations as in Figure 3.
|
|
View this table:
[in this window]
[in a new window]
|
Table 5. Prognostic Significance of Selected Variables for Ischemic Events According to Multivariate Cox Regression Analysis
|
|
Effect of eptifibatide treatment on platelet reactivity and ischemic events.
In patients not treated with eptifibatide, there was an 18% relative increase in mean platelet aggregation by LTA from baseline to 3 h after procedure (39 ± 17% to 48 ± 14%, p = 0.0004) followed by a return to preprocedural aggregation values by 18 to 24 h. However, an increase was not observed with the TEG assay (56 ± 21% to 55 ± 24, p = 0.793). In patients treated with eptifibatide, a 97% relative reduction in mean platelet aggregation was observed from baseline to 3 h as measured by LTA, compared with a 90% relative reduction observed with TEG. By 18 to 24 h, patients treated with eptifibatide had significant platelet inhibition compared with baseline (Figs. 6A and 6B). Within 1 month after procedure 6 patients suffered a recurrent ischemic event, 4 receiving clopidogrel alone and 2 receiving clopidogrel and eptifibatide. Within 1 year after procedure, recurrent ischemic events occurred in 80% of patients with HPR receiving clopidogrel alone versus 57% of patients with HPR receiving clopidogrel and eptifibatide. In the NPR group, 11% of patients receiving clopidogrel alone and 4% of patients receiving both clopidogrel and eptifibatide suffered recurrent ischemic events (Table 6). Although not statistically significant, this resulted in a 15% relative risk reduction in ischemic events 1 month after procedure and a 35% relative risk reduction in ischemic events 1 year after procedure (p = 0.56 and p = 0.325, respectively). Bleeding events occurred in 1 patient receiving clopidogrel alone (minor) and in 2 patients receiving clopidogrel and eptifibatide (1 major and 1 minor).
View larger version (25K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 6 A Comparison of Platelet Reactivity With and Without Eptifibatide
(A) Graph demonstrating mean 5 µmol/l ADP-induced platelet aggregation with and without eptifibatide measured by LTA at baseline, 3 h and 18 to 24 h after percutaneous coronary intervention (PCI). *p < 0.0001 for the change in platelet aggregation in patients receiving eptifibatide versus no eptifibatide.  p = 0.0004 for platelet aggregation 3 h after PCI in patients receiving eptifibatide versus baseline. (B) Graph demonstrating mean 2 µmol/l ADP-induced platelet aggregation with and without eptifibatide measured by TEG at baseline, 3 h and 18 to 24 h after PCI. *p < 0.0001 for change in platelet aggregation in patients receiving eptifibatide versus no eptifibatide. Abbreviations as in Figure 3.
|
|
|
Discussion
|
|---|
The current study demonstrates that patients receiving chronic clopidogrel therapy undergoing nonemergent PCI who exhibit high on-treatment preprocedural ADP-induced platelet aggregation as measured by LTA (50% ADP-induced aggregation) or TEG (70% ADP-induced aggregation) are at increased risk for recurrent ischemic events. Of 23 patients suffering recurrent ischemic events, 16 patients displayed HPR as measured by LTA, whereas 20 patients displayed HPR as measured by TEG. Moreover, mean platelet aggregation was significantly higher in patients suffering recurrent ischemic events than in patients without recurrent events. Of further interest was the observation that patients not treated with eptifibatide displayed an 18% increase in mean platelet aggregation from baseline to 3 h after procedure as measured by LTA. These findings suggest that selected patients exhibiting preprocedural platelet inhibition during chronic clopidogrel therapy might nevertheless remain at risk for periprocedural thrombotic events due to heightened platelet reactivity to ADP that occurs after stenting.
A possible explanation for the absence of an increase in platelet reactivity to ADP when studied by TEG involves the use of whole blood as compared with platelet-rich plasma. Heptinstall et al. (21) have demonstrated the important effects that leukocytes and erythrocytes have on adenine nucleotide metabolism that modify the overall response of platelets to ADP.
Our results are concordant with several previous studies that have demonstrated the relationship between insufficient platelet inhibition, postcoronary stent thrombosis, and ischemic cardiovascular events (4,5,10,11). The recent CREST study (Clopidogrel Effect on Platelet Reactivity in Patients With Stent Thrombosis) demonstrated significantly higher 5 µmol/l and 20 µmol/l LTA ADP-induced platelet aggregation in patients with stent thrombosis as compared with patients without stent thrombosis (4), and the PREPARE POST-STENTING (Platelet Reactivity in Patients and Recurrent Events Post-Stenting) study reported increased ADP-induced aggregation measured by TEG in patients suffering ischemic events compared with patients without events (5). Furthermore, Matetzky et al. (10) reported that patients in the highest quartile of ADP-induced aggregation who were stented for acute ST-segment elevation myocardial infarction had a 40% likelihood for a recurrent cardiovascular event within 6 months. A similar study by Barragan et al. (11) showed high P2Y12 receptor reactivity as measured by vasodilator-stimulated phosphoprotein (VASP) phosphorylation levels in patients with stent thrombosis. Each of these studies supports the notion that inadequate platelet inhibition, the occurrence of stent thrombosis, and recurrent ischemic events are significantly related.
This study is the first to correlate the occurrence of ischemic events with platelet reactivity to ADP in patients receiving chronic clopidogrel therapy undergoing non-emergent PCI. There is currently no existing standard of treatment for clopidogrel loading in these patients. The possibility of further inhibiting platelet reactivity in patients receiving chronic clopidogrel therapy with an additional 600-mg loading dose was demonstrated by Kastrati et al. (22), suggesting routine reloading with clopidogrel in all patients undergoing PCI regardless of ongoing clopidogrel treatment. In addition, Kastrati (22) has also suggested increasing the current clopidogrel maintenance dose to 150 mg qd to further inhibit ADP-induced aggregation. Moreover, our current study demonstrated that the administration of eptifibatide reduced periprocedural elevation in platelet reactivity measured by LTA. Because further platelet inhibition is attainable in patients receiving chronic clopidogrel therapy, and a reduction in platelet reactivity is associated with a decrease in ischemic complications, an additional loading dose of clopidogrel (300 mg or 600 mg), the use of a GP IIb/IIIa inhibitor or an increase in maintenance dose therapy to 150 mg qd are all therapeutic considerations for patients receiving chronic therapy undergoing non-emergent PCI.
Thrombelastography was implemented in the current study to assess its reliability as a monitoring tool for analyzing the response to antiplatelet therapy. The TEG, combined with the PlateletMapping assay, was able to identify a subtherapeutic response that highly correlated with the more labor intensive method of LTA. Eighty-seven percent of patients encountering recurrent ischemic events exhibited HPR that was identified by TEG. These findings are concordant with the results of the PREPARE POST-STENTING study (5). Therefore, this assay might affect the delivery of individualized antiplatelet therapy.
Study limitations.
Although the study strongly suggests that HPR is associated with increased ischemic events after PCI, the results overall are limited by a small sample size. Therefore, larger randomized clinical trials in this subset of patients are necessary to confirm our findings. A second limitation of the study is that patients were not given an additional loading dose of clopidogrel. The clinical benefit of reloading patients already treated with chronic clopidogrel therapy with a further 300- or 600-mg dose remains unclear. Moreover, inherent differences within our study population by virtue of their need for repeat PCI could have impacted the prevalence of high platelet reactivity. In addition, flow cytometric platelet surface P-selectin and GP IIb/IIIa expression were not measured for additional indicators of platelet reactivity to ADP. Finally, medication was not provided and distributed by our study. Therefore, clopidogrel noncompliance might have contributed to pre-PCI high platelet reactivity and could have affected long-term outcomes, because no additional loading dose was administered. However, preprocedural compliance to clopidogrel and aspirin was verified by nursing staff, and postprocedural compliance was assured through repetitive telephone contacts and outpatient source documentation.
In conclusion, patients receiving chronic clopidogrel therapy undergoing nonemergent PCI, who exhibit high on-treatment ADP-induced platelet aggregation by LTA or the TEG point-of-service device, are at increased risk for postprocedural ischemic events. Our data support a mechanistic link between the platelet physiologic response and clinical outcomes. The results of this study have potential implications for clinicians who do not administer additional clopidogrel (before or after PCI) to patients receiving chronic clopidogrel therapy. Platelet function testing might improve patient outcomes by assessing the risk for recurrent ischemic events and adjusting subsequent antiplatelet treatment. These treatments might include reloading with a dose of 300 mg or 600 mg of clopidogrel, additional antiplatelet treatment with a GP IIb/IIIa inhibitor, or an increased clopidogrel maintenance dose. Future prospective studies are required to determine the efficacy of these regimens in patients with HPR.
|
Footnotes
|
|---|
This study was supported by the Sinai Hospital of Baltimore, the National Institute of Health (NIH) grant 5R44HL059753-03, and a grant from Haemoscope Corporation, Niles, Illinois. Dr. Gurbel has received research funding from Haemoscope and NIH to study the physical properties of clot formation with respect to recurrent ischemic events postelective stenting; research funding from Schering and Millennium to study antiplatelet effects of clopidogrel and eptifibatide in elective stenting; and research grant funding from Bayer to study the antiplatelet effects of aspirin in outpatients.
|
References
|
|---|
1. Tantry US, Bliden KP, Gurbel PA. Resistance to antiplatelet drugs: current status and future research Expert Opin Pharmacother 2005;6:2027-2045.[CrossRef][Web of Science][Medline]2. Gurbel PA, Bliden KP, Hayes KM, Tantry U. Platelet activation in myocardial ischemic syndromes Expert Rev Cardiovasc Ther 2004;2:535-545.[CrossRef][Medline] 3. Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEARPLATELETS) study Circulation 2005;111:1153-1159. 4. Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study J Am Coll Cardiol 2005;46:1827-1832.[Abstract/Free Full Text] 5. Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study J Am Coll Cardiol 2005;46:1820-1826.[Abstract/Free Full Text] 6. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 2003;107:2908-2913. 7. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting J Am Coll Cardiol 2005;45:1392-1396.[Abstract/Free Full Text] 8. Tantry US, Bliden KP, Gurbel PA. What is the best measure of thrombotic risks- pretreatment platelet aggregation, clopidogrel responsiveness, or posttreatment platelet aggregation? Catheter Cardiovasc Interv 2005;66:597.[CrossRef][Web of Science][Medline] 9. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention Circulation 2005;111:2099-2106. 10. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 2004;109:3171-3175. 11. Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation Catheter Cardiovasc Interv 2003;59:295-302.[CrossRef][Web of Science][Medline] 12. Gurbel PA, Bliden KP, Tantry US. Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS-1b study. J Am Coll Cardiol 2006;48:2186–91. 13. Gurbel PA, Bliden KP. Durability of platelet inhibition by clopidogrel Am J Cardiol 2003;91:1123-1125.[CrossRef][Web of Science][Medline] 14. O'shea JC, Madan M, Cantor WJ, et al. Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention Am Heart J 2000;140:834-839.[CrossRef][Web of Science][Medline] 15. Rivard GE, Brummel-Ziedins KE, Mann KG, Fan L, Hofer A, Cohen E. Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thromboelastography J Thromb Haemost 2005;3:2039-2043.[CrossRef][Web of Science][Medline] 16. Kawasaki J, Katori N, Kodaka M, Miyao H, Tanaka K. Electron microscopic evaluations of clot morphology during thromboelastography Anesth Analg 2004;99:1440-1444.[Abstract/Free Full Text] 17. Bliden KP, Tantry U, Zaman K, et al. High platelet reactivity is a risk factor for post-discharge ischemic complications following elective coronary stenting J Am Coll Cardiol 2005;47:45B. 18. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation J Am Coll Cardiol 2005;46:1705-1709.[Abstract/Free Full Text] 19. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST-elevation MI: a method for prognostication and therapeutic decision making JAMA 2000;284:835-842.[Abstract/Free Full Text] 20. Singh M, Williams BA, Gersh BJ, et al. Geographical differences in the rates of angiographic restenosis and ischemia-driven target vessel revascularization after percutaneous coronary interventions: results from the Prevention of Restenosis With Tranilast and its Outcomes (PRESTO) Trial J Am Coll Cardiol 2006;47:34-39.[Abstract/Free Full Text] 21. Heptinstall S, Johnson A, Glenn JR, White AE. Adenine nucleotide metabolism in human blood—important roles for leukocytes and erythrocytes J Thromb Haemost 2005;10:2331-2339. 22. Kastrati A, Beckerath N, Joost A, Pogatsa-Murray G, Gorchakova O, Schomig A. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy Circulation 2004;110:1916-1919.
This article has been cited by other articles:
|
|
|
|
 
G. Dangas, R. Mehran, G. Guagliumi, A. Caixeta, B. Witzenbichler, J. Aoki, J. Z. Peruga, B. R. Brodie, D. Dudek, R. Kornowski, et al.
Role of Clopidogrel Loading Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty: Results From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
J. Am. Coll. Cardiol.,
October 6, 2009;
54(15):
1438 - 1446.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Shimbo, W. Chaplin, S. Kuruvilla, L. T. Wasson, D. Abraham, and M. M. Burg
Hostility and Platelet Reactivity in Individuals Without a History of Cardiovascular Disease Events
Psychosom Med,
September 1, 2009;
71(7):
741 - 747.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Shuldiner, J. R. O'Connell, K. P. Bliden, A. Gandhi, K. Ryan, R. B. Horenstein, C. M. Damcott, R. Pakyz, U. S. Tantry, Q. Gibson, et al.
Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
JAMA,
August 26, 2009;
302(8):
849 - 857.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Verstuyft, T. Simon, and R. B. Kim
Personalized medicine and antiplatelet therapy: ready for prime time?
Eur. Heart J.,
August 2, 2009;
30(16):
1943 - 1963.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L Bonello, A De Labriolle, M Scheinowitz, G Lemesle, P Roy, D H Steinberg, T L Pinto Slottow, R Pakala, A D Pichard, P Barragan, et al.
Emergence of the concept of platelet reactivity monitoring of response to thienopyridines
Heart,
August 1, 2009;
95(15):
1214 - 1219.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. B Norgard, K. D Mathews, and G. C Wall
Drug-Drug Interaction Between Clopidogrel and the Proton Pump Inhibitors
Ann. Pharmacother.,
July 1, 2009;
43(7):
1266 - 1274.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-Y. Chen, S.-W. Rha, Y.-J. Li, K. L. Poddar, Z. Jin, Y. Minami, L. Wang, E. J. Kim, C. G. Park, H. S. Seo, et al.
Triple Versus Dual Antiplatelet Therapy in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Circulation,
June 30, 2009;
119(25):
3207 - 3214.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C.Y. To, G. Armstrong, I. Zeng, and M. W.I. Webster
Noncardiac Surgery and Bleeding After Percutaneous Coronary Intervention
Circ Cardiovasc Interv,
June 1, 2009;
2(3):
213 - 221.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Price
Bedside Evaluation of Thienopyridine Antiplatelet Therapy
Circulation,
May 19, 2009;
119(19):
2625 - 2632.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. Wesley, F. X. McGowan, R. A. Castro, S. Dissanayake, D. Zurakowski, and J. A. DiNardo
The Effect of Milrinone on Platelet Activation as Determined by TEG(R) Platelet MappingTM
Anesth. Analg.,
May 1, 2009;
108(5):
1425 - 1429.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. C. Lau and P. A. Gurbel
The drug-drug interaction between proton pump inhibitors and clopidogrel
Can. Med. Assoc. J.,
March 31, 2009;
180(7):
699 - 700.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. H. Jeong, S.-W. Lee, B.-R. Choi, I.-S. Kim, M.-K. Seo, C. H. Kwak, J.-Y. Hwang, and S.-W. Park
Randomized Comparison of Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With High Post-Treatment Platelet Reactivity Results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) Randomized Study.
J. Am. Coll. Cardiol.,
March 31, 2009;
53(13):
1101 - 1109.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Kuliczkowski, A. Witkowski, L. Polonski, C. Watala, K. Filipiak, A. Budaj, J. Golanski, D. Sitkiewicz, J. Pregowski, J. Gorski, et al.
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology
Eur. Heart J.,
February 2, 2009;
30(4):
426 - 435.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Scott, R. M Norwood, and D. Parra
P2Y12 Inhibitors in Cardiovascular Disease: Focus on Prasugrel
Ann. Pharmacother.,
January 1, 2009;
43(1):
64 - 76.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Erlinge, C. Varenhorst, O. O. Braun, S. James, K. J. Winters, J. A. Jakubowski, J. T. Brandt, A. Sugidachi, A. Siegbahn, and L. Wallentin
Patients With Poor Responsiveness to Thienopyridine Treatment or With Diabetes Have Lower Levels of Circulating Active Metabolite, but Their Platelets Respond Normally to Active Metabolite Added Ex Vivo
J. Am. Coll. Cardiol.,
December 9, 2008;
52(24):
1968 - 1977.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Cairns and J. Eikelboom
The Pursuit of Clinically Relevant Measures of Platelet Function After Antiplatelet Drug Therapy
J. Am. Coll. Cardiol.,
December 9, 2008;
52(24):
1978 - 1980.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Bhindi, O. Ormerod, J. Newton, A.P. Banning, and L. Testa
Interaction between statins and clopidogrel: is there anything clinically relevant?
QJM,
December 1, 2008;
101(12):
915 - 925.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Patti, A. Nusca, F. Mangiacapra, L. Gatto, A. D'Ambrosio, and G. Di Sciascio
Point-of-Care Measurement of Clopidogrel Responsiveness Predicts Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention: Results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) Study
J. Am. Coll. Cardiol.,
September 30, 2008;
52(14):
1128 - 1133.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. O. Williams and J. D. Abbott
What to Do With Patients Receiving Long-Term Clopidogrel: Reload or Relax?
Circulation,
September 16, 2008;
118(12):
1219 - 1222.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-P. Collet, J. Silvain, A. Landivier, M.-L. Tanguy, G. Cayla, A. Bellemain, N. Vignolles, S. Gallier, F. Beygui, A. Pena, et al.
Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose: The Reload With Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term With Dual Antiplatelet Therapy (RELOAD) Study
Circulation,
September 16, 2008;
118(12):
1225 - 1233.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-H. Jeong, I.-S. Kim, B.-R. Choi, C. H. Kwak, and J.-Y. Hwang
The optimal threshold of high post-treatment platelet reactivity could be defined by a point-of-care VerifyNow P2Y12 assay
Eur. Heart J.,
September 1, 2008;
29(17):
2186 - 2187.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. P. Bliden, J. DiChiara, L. Lawal, A. Singla, M. J. Antonino, B. A. Baker, W. L. Bailey, U. S. Tantry, and P. A. Gurbel
The Association of Cigarette Smoking With Enhanced Platelet Inhibition by Clopidogrel
J. Am. Coll. Cardiol.,
August 12, 2008;
52(7):
531 - 533.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Yano, T. Ohmori, S. Hoshide, S. Madoiwa, K. Yamamoto, T. Katsuki, T. Mitsuhashi, J. Mimuro, K. Shimada, K. Kario, et al.
Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad
Eur. Heart J.,
July 2, 2008;
29(14):
1729 - 1738.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The year in interventional cardiology.
J. Am. Coll. Cardiol.,
June 17, 2008;
51(24):
2355 - 2369.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Trenk, W. Hochholzer, M. F. Fromm, L.-E. Chialda, A. Pahl, C. M. Valina, C. Stratz, P. Schmiebusch, H.-P. Bestehorn, H. J. Buttner, et al.
Cytochrome P450 2C19 681G>A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal Stents
J. Am. Coll. Cardiol.,
May 20, 2008;
51(20):
1925 - 1934.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-P. Bassand
Unmet needs in antiplatelet therapy
Eur. Heart J. Suppl.,
May 1, 2008;
10(suppl_D):
D3 - D11.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Wallentin
Dual antiplatelet therapy in the drug-eluting stent era
Eur. Heart J. Suppl.,
May 1, 2008;
10(suppl_D):
D38 - D44.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Kereiakes and P. A. Gurbel
Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention
J. Am. Coll. Cardiol. Intv.,
April 1, 2008;
1(2):
111 - 121.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. L. L'Allier, G. Ducrocq, N. Pranno, S. Noble, R. Ibrahim, J. C. Gregoire, F. Azzari, A. Nozza, C. Berry, S. Doucet, et al.
Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study.
J. Am. Coll. Cardiol.,
March 18, 2008;
51(11):
1066 - 1072.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Michelson
P2Y12 Antagonism: Promises and Challenges
Arterioscler Thromb Vasc Biol,
March 1, 2008;
28(3):
s33 - s38.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al.
Highlights of the year in JACC 2007.
J. Am. Coll. Cardiol.,
January 29, 2008;
51(4):
490 - 512.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Gachet and B. Aleil
Testing antiplatelet therapy
Eur. Heart J. Suppl.,
January 1, 2008;
10(suppl_A):
A28 - A34.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Gurbel, R. C. Becker, K. G. Mann, S. R. Steinhubl, and A. D. Michelson
Platelet Function Monitoring in Patients With Coronary Artery Disease
J. Am. Coll. Cardiol.,
November 6, 2007;
50(19):
1822 - 1834.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Angiolillo, E. Bernardo, M. Sabate, P. Jimenez-Quevedo, M. A. Costa, J. Palazuelos, R. Hernandez-Antolin, R. Moreno, J. Escaned, F. Alfonso, et al.
Impact of Platelet Reactivity on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
J. Am. Coll. Cardiol.,
October 16, 2007;
50(16):
1541 - 1547.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bode and M. Zehender
The use of antiplatelet agents following percutaneous coronary intervention: focus on late stent thrombosis
Eur. Heart J. Suppl.,
August 1, 2007;
9(suppl_D):
D10 - D19.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Jaffe and B. H. Strauss
Late and Very Late Thrombosis of Drug-Eluting Stents: Evolving Concepts and Perspectives
J. Am. Coll. Cardiol.,
July 10, 2007;
50(2):
119 - 127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Moliterno and C. L. Campbell
Unraveling Questions Surrounding Clopidogrel Resistance and Stent Thrombosis: One Less Snag
J. Am. Coll. Cardiol.,
June 19, 2007;
49(24):
2318 - 2319.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. T. Dove, D. J. Moliterno, W. D. Weaver, and M. E. Shelton
President's Page: Drug-Eluting Stents in Contemporary Practice--A Call for a Real-World, Open-Entry, Device-Tracking Registry
J. Am. Coll. Cardiol.,
June 5, 2007;
49(22):
2223 - 2226.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, F. Alfonso, C. Macaya, T. A. Bass, and M. A. Costa
Variability in Individual Responsiveness to Clopidogrel: Clinical Implications, Management, and Future Perspectives
J. Am. Coll. Cardiol.,
April 10, 2007;
49(14):
1505 - 1516.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
Top
Abstract
Methods
